Introduction
============

Obesity has reached epidemic proportions globally, with more than one billion adults overweight and at least 300 million of them clinically obese. In addition, at least 155 million children worldwide are overweight or obese, according to the International Obesity Task Force (Hossain et al., [@B17]). Obesity constitutes a substantial risk factor for hypertension, type 2 diabetes, and cardiovascular diseases implying tremendous burdens for the public health care system. White adipose tissue (WAT) plays a central role in the control of energy homeostasis (Ailhaud et al., [@B1]; Rosen and Spiegelman, [@B27]). In contrast to WAT, brown adipose tissue (BAT) is specialized in adaptive thermogenesis in which the uncoupling protein 1 (UCP1) plays a key role (Golozoubova et al., [@B14]). The involvement of BAT in diet-induced thermogenesis has been recently shown in UCP1-ablated mice raised at thermoneutrality (Feldmann et al., [@B11]). Of utmost interest, recent data show that active BAT is indeed present as discrete and small depots in healthy adult individuals (Nedergaard et al., [@B19]; Cypess et al., [@B8]; Saito et al., [@B28]; Van Marken Lichtenbelt et al., [@B35]; Virtanen et al., [@B37]; Zingaretti et al., [@B43]) and represents a new target to fight obesity (Fruhbeck et al., [@B13]; Whittle et al., [@B38]).

At the cellular level, a myogenic signature of brown adipocytes and cell sorting of muscle and WAT derived progenitors favor a distinct origin from that of white adipocytes (Timmons et al., [@B32]; Crisan et al., [@B7]). *In vivo* lineage studies showed that brown adipocytes from brown-fat depots share a common developmental origin with myoblasts (Seale et al., [@B30]). However, islands of brown adipocytes are also detected in white fat depots of rodents following chronic exposure to cold or pharmacological stimulation of β3-adrenoreceptor (β3-AR). There is indeed evidence that white adipocytes can be converted to brown-like fat cells (Tiraby et al., [@B33]; Cinti, [@B4],[@B5]; Barbatelli et al., [@B2]). Within traditional WAT depots, a particular type of adipocytes occurs in rodents, corresponding to the "brite" (brown-in-white) adipocytes. These cells express UCP1 and exhibit *in vitro* a thermogenic response to β-AR agonists (Petrovic et al., [@B21]) that could explain UCP1 expressing cells present as islets surrounded by white adipocytes (Cousin et al., [@B6]; Xue et al., [@B40]). Most importantly, *in vivo*, the capacity of obese mice to reduce their fat mass in response to adrenergic stimulation by cold or β3-AR agonist does not depend upon BAT whose amount is genetically invariant among mouse strains but depends upon a genetic variability which affects the development of "brite" adipocytes within WAT depots (Guerra et al., [@B15]; Xue et al., [@B39]). Other external cues are favoring the brown-fat differentiation, e.g., Hedgehog signaling has been characterized as a determinant of brown-fat cell fate (Pospisilik et al., [@B23]) whereas among bone morphogenetic proteins (BMPs), BMP7 specifically promotes brown adipogenesis of murine multipotent mesenchymal stem cells (Tseng et al., [@B34]; Schulz et al., [@B29]).

We have reported the characterization of mesenchymal stem cells from human adipose tissue of young male and female donors \[termed human multipotent adipose-derived stem cells (hMADS)\] which exhibit at a clonal level a normal karyotype, self-renewal ability, the absence of tumorigenicity (Rodriguez et al., [@B26], [@B24]; Zaragosi et al., [@B41]; Elabd et al., [@B10]; Fontaine et al., [@B12]), and are able to convert into functional brown-like adipocytes (Elabd et al., [@B9]). Owing to recent data showing that thermogenic adipocytes from BAT and WAT originate from distinct origin, the question raised whether UCP1-positive hMADS adipocytes from both sexes are classical brown or "brite" adipocytes. Herein we provide evidence at the molecular level that these cells share similarities with mouse brite adipocytes. However, in contrast to mouse cellular models, brown adipogenesis is only slightly induced by BMP7 treatment and not modulated by activation of the Hedgehog pathway. Thus hMADS cells represent a suitable human cell model to gain insights in the formation of brite adipocytes that could help to dissipate caloric excess intake.

Materials and Methods {#s1}
=====================

Reagents
--------

Cell culture media, serum, buffers, and trypsin were purchased from Lonza Verviers (Verviers, Belgium) and cell culture reagents from Sigma-Aldrich Chimie (Saint-Quentin Fallavier, France). Rosiglitazone was purchased from BertinPharma (Montigny le bretonneux, France).

Cell culture
------------

The establishment and characterization of the multipotency and self-renewal capacity of hMADS cells have been described (Rodriguez et al., [@B26], [@B25]; Elabd et al., [@B10], [@B9]). In the experiments reported herein hMADS-1, 2, and 3 cells, established respectively, from the umbilical fat pad of a 31-month-old female donor, from the pubic region fat pad of a 5-year-old male donor and the prepubic fat pad of a 4-month-old male, were used between passages 16 and 35 corresponding from 35 to 100 population doublings. Cells were seeded at a density of 4500 cells/cm^2^ in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS, 2.5 ng/ml hFGF2, 60 μg/ml penicillin, and 50 μg/ml streptomycin. The medium was changed every other day and hFGF2 was removed when cells reached confluence and were triggered for differentiation at day 2 post-confluence (designated as day 0). Cells were then maintained in DMEM/Ham's F12 media supplemented with 10 μg/ml transferrin, 0.85 μM insulin, 0.2 nM triiodothyronine, 1 μM dexamethasone, 500 μM isobutyl-methylxanthine. Three days later, the medium was changed (dexamethasone and isobutyl-methylxanthine were omitted) and 100 nM rosiglitazone were added for the indicated periods. Media were then changed every other day and cells used at the indicated days. Glycerol-3-phosphate dehydrogenase (GPDH) activity measurements and Oil Red O staining were performed as described previously (Negrel et al., [@B20]; Bezy et al., [@B3]).

Isolation and analysis of RNA
-----------------------------

Total RNA was extracted using TRI-Reagent kit (Euromedex, Souffelweyersheim, France) according to the manufacturer's instructions. Quality control for purity and integrity of RNA were tested by OD (260/280 nM) measurements and ethidium bromide-stained agarose analysis. Reverse transcription-polymerase chain reaction (RT-PCR) analysis was conducted as described previously (Rodriguez et al., [@B26]; Bezy et al., [@B3]; Zaragosi et al., [@B41]; Elabd et al., [@B10]). Primer sequences, designed using Primer Express software (Applied Biosystems, Courtaboeuf, France), are listed in Table [1](#T1){ref-type="table"} and were tested for their specificity, efficiency, reproducibility, and dynamic range. For quantitative PCR, final reaction volume was 20 μl using SYBR green master mix (Eurogentec, Angers, France) and assays were run on an ABI Prism 7700 real-time PCR machine (PerkinElmer Life and Analytical Sciences, Boston, MA, USA). An aliquot of PCR products was analyzed on 2% ethidium bromide-stained agarose. The expression of selected genes was normalized to that of TATA-box binding protein (TBP) gene and quantified using the comparative-ΔCt method. TBP expression did not vary along the adipocyte differentiation of hMADS cells; we used also 36B4 and POLR2A genes as housekeeping genes which gave similar data. Human skeletal muscle RNA extracts were obtained from a previous study (Pisani et al., [@B22]).

###### 

**Sequence of primers used for gene expression analysis**.

  Gene      Complete name                                      Forward primer                Reverse primer             Accession N°
  --------- -------------------------------------------------- ----------------------------- -------------------------- -----------------
  UCP1      Uncoupling protein 1                               GTGTGCCCAACTGTGCAATG          CCAGGATCCAAGTCGCAAGA       NM021833
  UCP2      Uncoupling protein 2                               GGCCTCACCGTGAGACCTTAC         TGGCCTTGAACCCAACCAT        NM003355
  UCP3      Uncoupling protein 3                               TCAGCCCCCTCGACTGTATG          ACTTTCATCAGGGCCCGTTT       NM003356.3
  PPARγ     Peroxisome proliferator activated receptor gamma   AGCCTCATGAAGAGCCTTCCA         TCCGGAAGAAACCCTTGCA        NM005037
  PGC-1α    PPARg coactivator 1 alpha                          CTGTGTCACCACCCAAATCCTTAT      TGTGTCGAGAAAAGGACCTTGA     NM013261
  PGC-1β    PPARg coactivator 1 beta                           GCGAGAAGTACGGCTTCATCAC        CAGCGCCCTTTGTCAAAGAG       NM13 3263
  PRDM16    PR domain containing 16                            GAAACTTTATTGCCAATAGTGAGATGA   CCGTCCACGATCTGCATGT        NM022114
  CIDEA     Cell death-inducing DFFA-like effector A           GGCAGGTTCACGTGTGGATA          GAAACACAGTGTTTGGCTCAAGA    NM001279
  CPT1B     Carnitine palmitoyltransferase 1B                  AAACAGTGCCAGGCGGTC            CGTCTGCCAACGCCTTG          NM_152246
  ELOVL3    Fatty acid elongase 3                              TTGGACCTTGACTTCTGCAA          GGGCTATGGGGAATGAGG         NM152310.1
  AGT       Angiotensinogen                                    ACCTACGTCCACTTCCAAGG          GTTGTCCACCCAGAACTCCT       NM_00 0029.3
  MEOX2     Mesenchyme homeobox 2                              AGAGGAAAAGCGACAGCTCA          AAGTTCTCTGATTTGCTCTTTGGT   NM005924.4
  ZIC1      Zic family member 1                                TGGCGCTCACATTCCTCTAT          GCATCTCAGCCCCCTAAAA        NM_00 3412.3
  LHX8      LIM homeobox 8                                     GTCGGACGTCTGGGTTTG            ACGGAAGAAATAGGGGAAGC       NM001001933.1
  CtBP1     C-terminal binding protein 1                       GCCTCAACGAGCACAACCA           ACCAGGAAGGCCCCTTGTC        NM001012614.1
  CtBP2     C-terminal binding protein 2                       CTGGTGGACGAGAAAGCCTTA         GGCTGCCCCTCGTATCCT         NM022802.2
  NRIP1     Nuclear receptor interacting protein 1             TTGGAGACAGACGAACACTGA         TCTACGCAAGGAGGAGGAGA       NM_00 3489.3
  LXR       Liver-X-receptor                                   CAGGGCTCCAGAAAGAGATG          ACAGCTCCACCGCAGAGT         NM005693.2
  GPBAR1    G protein-coupled bile acid receptor 1             CCCAGGCTATCTTCCCAGC           AGCAGGAGCCCATAGACTTCG      NM001077191.1
  DiO2      Deiodinase type 2                                  GTCACTGGTCAGCGTGGTTTT         TTCTTCACATCCCCCAATCCT      NM 000793.5
  COX1      Cyclooxygenase 1                                   AGCAGCTGAGTGGCTATTTCCT        CCAGTTCCAATACCGCAACCG      NM080591.1
  COX2      Cyclooxygenase 2                                   GAATCATTCACCAGGCAAATTG        TCTGTACTGCGGGTGGAACA       NM_00 0963.2
  PTGiS     Prostaglandine I2 synthase                         GCCACATAGCTCATAAGCTGTAGAAC    AGTTGCTCATCCAGCATTTGC      NM000961.3
  PTGiR     Prostaglandine I2 receptor                         AGCCTGGGCAAGACTGGAG           TAGGTGAGGTTCCTGCACGAA      NM_00 0960.3
  TPK1      Thiamin pyrophosphokinase 1                        CAAGGTGTTCGTGGTTGGC           TTGAGTGAGGGCCTCTGGAC       NM_00 1042482.1
  FABP4     Fatty acid binding protein 4                       TGTGCAGAAATGGGATGGAAA         CAACGTCCCTTGGCTTATGCT      NM_00 1442.2
  ADIPOQ    Adiponectin                                        GCAGTCTGTGGTTCTGATTCCATAC     GCCCTTGAGTCGTGGTTTCC       NM 00 479 7.3
  RARRES2   Chemerin                                           GGAATATTTGTGAGGCTGGAA         CAGGCATTTCCGTTTCCTC        NM002889.3
  PANK3     Pantothenate kinase 3                              CATTGCAGACGGTGCTATGT          GTTTGTGCAGGTGGAGGTTT       NM024594.3
  HOXC9     Homeobox C9                                        CAGCAAGCACAAAGAGGAGA          CGACGGTCCCTGGTTAAATAC      NM006897.1
  DPT       Dermatopontin                                      CGAGGAGCAACAACCACTTT          CGGCACATTATGAACTTCCA       NM001937.4
  LEP       Leptin                                             AGGGAGACCGAGCGCTTTC           TGCATCTCCACACACCAAACC      NM_00 0230.2
  Gli1      Glioma-associated oncogene homolog 1               TGCAGTAAAGCCTTCAGCAATG        TTTTCGCAGCGAGCTAGGAT       NM001167609.1
  Myf5      Myogenic factor 5                                  GATCACCTCCTCAGAGCAACCT        GTGCTGGCAACTGGAGAGAGA      NM005593.2
  TBP       TATA-box binding protein                           CACGAACCACGGCACTGATT          TTTTCTTGCTGCCAGTCTGGAC     NM003194

Mitochondria analysis
---------------------

Living cells were submitted to 100 nM MitoTracker Red FM (Invitrogen) for 45 min at 37°C. Cells were finally washed with prewarmed culture medium and visualized with an Axiovert microscope (Carl Zeiss, Le Pecq, France) and pictures were captured and treated with AxioVision software (Carl Zeiss).

Cytochrome c oxidase activity determinations
--------------------------------------------

Cells were disrupted using a polytron in 10 mM Tris pH 8, 1 mM EDTA, and 0.25 M Sucrose containing protease inhibitors. Cell lysate was centrifuged at 750 *g* for 10 min with a pellet corresponding to a nuclear-enriched fraction. The supernatant was then centrifuged at 10 000 *g* for 20 min, the pellet corresponding to a mitochondrial-enriched fraction. The mitochondrial-enriched fraction was used to determine Cytochrome c Oxidase activity according to manufacturer's instructions (Cytochrome c Oxidase Assay kit, Sigma).

Statistical analysis
--------------------

Data are expressed as mean values ± SEM and are analyzed using the 2-tailed Student's *t*-test. Differences were considered statistically significant at *P* ≤ 0.05.

Results
=======

UCP1, 2, and 3 expression during hMADS cell differentiation
-----------------------------------------------------------

We showed previously that hMADS cells were able to differentiate into white and brown adipocytes depending on the length of activation of PPARγ by rosiglitazone (Elabd et al., [@B9]). For hMADS-1 cells, originally established from the umbilical fat pad of a 31-month-old female donor, a 6-day exposure to rosiglitazone (between days 3 and 9) proved to be optimal for the cells to become white adipocytes. As shown in Figures [1](#F1){ref-type="fig"}A,B, further exposure of the cells to rosiglitazone did not alter the overall adipogenesis level *per se* since treatment between days 3 and 16 brought no change in triglyceride accumulation (Oil Red O staining) and GPDH activity. Under this condition, as shown in Figure [1](#F1){ref-type="fig"}C, a dramatic increase in the expression of UCP1 mRNA was observed. Interestingly, when hMADS-1 cells were first differentiated as above into white adipocytes and rosiglitazone being removed for the next 5 days, a further 2-day rosiglitazone exposure (between days 14 and 16) was sufficient to stimulate the expression of UCP1 (Figure [1](#F1){ref-type="fig"}C). In order to extend these observations, hMADS-2 and hMADS-3 cells, established respectively from the pubic fat pad of a 5-year-old male donor and the prepubic fat pad of a 4-month-old male, were used and gave similar results (Figure [1](#F1){ref-type="fig"}C). Under these conditions, UCP1 protein could be detected by immunoblotting analysis (data not shown).

![**Conversion of hMADS cells into brown- like adipocytes**. hMADS-1, 2, and 3 cells were induced to differentiate into adipocytes as described under the Section "[Materials and Methods](#s1){ref-type="sec"}." Hundred nanometer rosiglitazone was added during the indicated periods of treatment. At day 16, **(A)** cells were fixed and stained by Oil Red O, **(B)** GPDH activity was determined, and **(C--E)** UCP1, UCP2, and UCP3 mRNA levels, respectively, were measured by quantitative RT-PCR. Results are mean ± SEM of three **(B,C)** or two **(D,E)** independent experiments. Results in **(C)** and **(D)** are expressed by taking as 100% the value obtained for rosiglitazone treatment between days 3 and 16. In **(E)**, human skeletal muscle cells were used as positive control for UCP3 expression. Results in **(E)** are expressed taking as 100% the value obtained for skeletal muscle cells. \**p* \< 0.05 vs. cells treated between days 3 and 9.](fendo-02-00087-g001){#F1}

We then measured for the expression of two other members of the UCP family, UCP2 and UCP3. The expression of UCP2 mRNA was induced during adipogenesis of hMADS-1, 2, and 3 cells, and its expression was partially but not significantly enhanced by the duration of rosiglitazone treatment (Figure [1](#F1){ref-type="fig"}D). Interestingly, UCP3 mRNA was barely detected (100--200 times lower as compared to skeletal muscle cells), was not induced during adipogenesis and remained insensitive to rosiglitazone treatment (Figure [1](#F1){ref-type="fig"}E).

UCP1 induction is dependent upon PPARγ activation
-------------------------------------------------

Among members of the thiazolidinedione family, rosiglitazone is known as a high-affinity ligand of PPARγ. We therefore carried out a comparative study with other thiazolidinediones, i.e., troglitazone and ciglitazone, with respect to the induction of UCP1 gene expression. For this purpose, hMADS-2 cells were first differentiated into white adipocytes as above, i.e., rosiglitazone treatment between days 3 and 9 followed by its removal for the next 5 days, were then exposed to increasing concentrations of various thiazolidinediones between days 14 and 16. The levels of UCP1 mRNA were analyzed by quantitative RT-PCR at day 16. As shown in Figure [2](#F2){ref-type="fig"}A, troglitazone and ciglitazone were able to induce UCP1 expression in a dose-dependent manner. Clearly, the potency of rosiglitazone was already maximal at a dose where the effects of troglitazone and ciglitazone were weak. In order to gain further insights into the critical role of PPARγ, we tested whether a specific PPARγ antagonist (GW9662) was able to abolish the effect of rosiglitazone on UCP1 expression. As above, hMADS-2 cells were first differentiated into white adipocytes, then treated or not with 100 nM rosiglitazone in the presence or absence of the PPARγ antagonist. As shown in Figure [2](#F2){ref-type="fig"}B the rosiglitazone-induced UCP1 mRNA expression was abolished in a dose-dependent manner by GW9662. Of note, GW9662 showed no effect on untreated hMADS cells. Similar data were observed using hMADS-3 cells (data not shown). Altogether, these observations demonstrated that induction of UCP1 was dependent on PPARγ activation and that rosiglitazone was the most efficient agonist in this process.

![**Activation of PPARγ is involved in the conversion of white to brown adipocytes**. hMADS-2 cells were induced to differentiate into white adipocytes in the presence of 100 nM rosiglitazone between days 3 and 9, and then treated with various component as indicated between days 14 and 16. **(A)** Effect of various PPARγ agonists (Rosiglitazone, Troglitazone, and Ciglitazone) analyzed by quantitative RT-PCR of UCP1 gene expression. **(B)** Effect of the PPARγ antagonist GW9662 on UCP1 expression stimulated by rosiglitazone. Results are the mean ± SEM of two independent experiments. Results are expressed by taking as 100% the value obtained at 100 nM rosiglitazone. \**p *\< 0.05 vs. cells exposed to 100 nM rosiglitazone between days 3--9 and days 14--16.](fendo-02-00087-g002){#F2}

Characterization of mitochondriogenesis in differentiated hMADS adipocytes
--------------------------------------------------------------------------

As abundance of mitochondria is higher in brown as compared to white fat cells, we tested whether mitochondriogenesis was affected in the "browning" process of hMADS cells. Clearly, more mitochondria were observed in brown-like adipocytes as compared to white adipocytes (Figure [3](#F3){ref-type="fig"}A). This observation was further supported by quantitative RT-PCR analysis of CPT1B, a fatty acid transporter of the outer mitochondrial membrane (Figure [3](#F3){ref-type="fig"}B). Under these conditions, CPT1B mRNA levels were 10-fold higher in brown-like adipocytes as compared to white adipocytes. Furthermore, the increase of CPT1B mRNA levels upon rosiglitazone treatment was similar to that observed for UCP1 (Figure [1](#F1){ref-type="fig"}C).

![**Mitochondriogenesis of hMADS cells after conversion to brown-like adipocytes**. hMADS-2 cells were induced to differentiate into adipocytes in the presence of 100 nM rosiglitazone between days 3 and 9 or between days 3 and 16. Alternatively, after removal at day 9, rosiglitazone was re-added or not at day 14 for 2 days. **(A)** Mitochondria visualized by epifluorescence in living cells in the presence of the mitotracker dye, **(B)** CPT1B mRNA levels determined at day 16 by quantitative RT-PCR in hMADS-1, 2, and 3 cells and **(C)** Cytochrome c oxidase activity determined at day 16. Results are mean ± SEM **(B,C)** and are representative experiments **(A)** of three independent experiments performed on different series of cells. \**p *\< 0.05 vs. cells treated between days 3 and 9.](fendo-02-00087-g003){#F3}

Finally, we measured the Cytochrome c oxidase activity in this fraction as an index of respiratory chain activity. As expected, Cytochrome c oxidase activity was higher in UCP1-containing fractions from hMADS cells chronically treated as compared to cells treated between days 3 and 9 (Figure [3](#F3){ref-type="fig"}C). Thus, hMADS adipocytes expressing UCP1 display a significant increase in mitochondriogenesis accompanied by an increase in their respiratory activity; both indicating the acquisition of a brown-like phenotype. As brown-like adipocytes arise from white adipocytes, brown-like adipocytes can be defined at first sight under our conditions as brite adipocytes.

Analysis of gene expression in hMADS-derived brite adipocytes
-------------------------------------------------------------

Recently, studies of mouse model have described genes with differential expression in white vs. brown adipocytes (Vernochet et al., [@B36]; Petrovic et al., [@B21]). Therefore we aimed at analyzing the expression of a large set of these genes in white vs. brown-like hMADS adipocytes.

First, we analyzed the expression of Myf5 known to be a molecular signature common to brown-fat and skeletal muscle cells (Seale et al., [@B30]). Myf5 expression was not detectable in proliferating or differentiated hMADS cells originating from three donors (data not shown).

Table [2](#T2){ref-type="table"} summarized the expression values (ΔCt referred to TBP) of different genes in hMADS cells at day 9 of adipocyte differentiation as well as day 16 of white and brite differentiation of hMADS-2 and 3 cells. White and brite hMADS adipocytes expressed classical adipogenic markers (FABP4, ADIPOQ, RARRES2, PANK3, PPARγ, and low level of LXR) at similar levels. In addition, hMADS brite adipocytes expressed UCP1, CPT1B, CIDEA, and ELOVL3, four genes found to be highly expressed in mouse brite adipocytes (Petrovic et al., [@B21]). Conversely, these cells did not express ZIC1 and LHX8, two genuine brown adipocyte specific genes (Vernochet et al., [@B36]). Interestingly, hMADS cells expressed PRDM16, MEOX2, and AGT at the same level in both white and brite adipocytes. With respect to white adipocyte specific genes, it is noticeable that leptin (LEP) and DPT but not HOXC9 levels decreased with brite adipocyte formation.

###### 

**Analysis of white and brown specific markers**.

                                                                     hMADS-2   hMADS-3                                                              
  -------------------------------------------------------- --------- --------- --------- ------------- ------------- -------- ------- ------------- -------------
  Brown markers                                            UCP1      0.376     5.231     138.1         **26.393**    0.060    2.400   45.50         **18.958**
                                                           CPT1B     0.322     0.147     1.757         **11.949**    0.020    0.110   1.340         **12.182**
                                                           CIDEA     0.019     0.041     0.076         **1.857**     0.020    0.010   0.028         **2.800**
                                                           ELOVL3    0.449     1.246     2.006         **1.610**     0.600    0.788   1.332         **1.691**
                                                           AGT       0.805     0.140     0.131         0.938         0.275    0.059   0.033         *0.564*
                                                           PRDM16    0.027     0.024     0.017         0.731         0.028    0.036   0.027         0.750
                                                           MEOX 2    0.016     0.019     0.020         1.035         0.030    0.013   0.009         0.705
                                                           ZIC1      nd        nd        nd            nd            0.027    0.018   0.018         1.027
                                                           LHX8      nd        nd        nd            nd            nd       nd      nd            nd
  Brown/white markers                                      FABP4     263.0     94.0      305.0         **3.245**     317.0    206.0   390.0         **1.893**
                                                           ADIPOQ    105.0     31.0      138.0         **4.452**     69.00    27.00   96.00         **3.556**
                                                           RARRES2   0.237     0.513     0.650         1.266         1.002    1.976   1.425         0.721
                                                           PANK 3    2.397     5.035     5.996         1.191         0.979    3.421   2.454         0.717
  White markers                                            HoxC9     0.679     0.514     0.710         1.381         0.591    0.648   0.550         0.849
                                                           DPT       3.264     1.964     1.096         ***0.558***   18.306   7.310   6.908         0.945
                                                           LEP       0.707     0.406     0.25          ***0.616***   1.392    0.244   0.158         ***0.648***
  PPAR complex                                             PGC1α     0.431     0.340     0.494         1.453         0.940    0.320   0.400         1.250
                                                           PGC1β     0.229     0.211     0.220         1.042         0.190    0.190   0.240         1.263
                                                           PPARγ     3.145     13.310    10.598        0.796         10.200   9.500   10.500        1.105
                                                           CtBP1     2.260     7.300     6.200         0.849         1.820    6.100   6.400         1.049
                                                           CtBP2     1.110     1.910     18.200        **9.529**     2.280    2.540   11.700        **4.606**
                                                           NRIP1     1.442     1.066     1.597         1.499         1.140    0.630   0.750         1.190
                                                           LXR       0.110     8.000     12.600        **1.575**     0.150    8.500   20.300        **2.388**
  Receptor/enzyme involved in white and brown activation   GPBAR1    0.309     0.120     0.209         **1.743**     0.118    0.056   0.084         1.489
  DiO2                                                     0.060     0.051     0.056     1.103         0.041         0.055    0.057   1.026         
  COX2                                                     0.004     0.019     0.010     ***0.538***   0.030         0.041    0.039   0.951         
  COX1                                                     0.708     0.135     0.125     0.926         0.440         0.140    0.150   1.071         
  PTGiS                                                    1.416     nd        nd        nd            0.390         0.910    0.440   ***0.484***   
  PTGiR                                                    0.008     0.123     0.145     1.178         0.040         0.080    0.118   1.475         
  TPK1                                                     1.621     1.551     1.292     0.833         0.633         1.040    0.841   0.809         

*hMADS-2 and 3 cells were induced to differentiate into adipocytes in the presence of 100 nM rosiglitazone between days 3 and 9 or between days 3 and 16. Expression of various markers described previously was analyzed by quantitative RT-PCR. The expression values (ΔCt referred to TBP) mRNA in hMADS cells at the indicated. Genes indicated in italics and bold are highly expressed in white adipocyte and in brown adipocyte conditions, respectively*.

Co-activators (PGC1α, PGC1β) and co-repressors (CtBP1, CtBP2, NRIP1) of PPARγ were also expressed, demonstrating the ability of these cells to modulate PPAR signaling pathways. hMADS cells also expressed other classical components of brown adipocyte signaling such as DiO2 (thyroid hormone pathway), COX1, COX2, PGTiS, and PGTiR (arachidonic acid pathway) and interestingly, an increase in the bile acid receptor, GPBAR1.

Altogether, these observations clearly confirmed the "brite" phenotype of hMADS adipocytes as they display both an origin and a molecular signature distinct from those of genuine brown adipocytes.

Effects of Hedgehog and BMP signaling effectors on brite hMADS cell formation
-----------------------------------------------------------------------------

As conversion of hMADS cells into brite adipocytes is dependent upon PPARγ activation, we became interested in deciphering pathways that are independent of rosiglitazone treatment. It has been shown in mouse models that Hedgehog and BMP pathways modulated the formation of brown adipocytes (Lee et al., [@B18]; Pospisilik et al., [@B23]; Schulz et al., [@B29]). We analyzed UCP1 expression after activation of the Hedgehog pathway, using two known activators of smoothen, i.e., purmorphamine and smoothened agonist (SAG). hMADS cells that were differentiated in the presence of rosiglitazone either between day 3 and 9 or between day 3 and 16 were exposed to the two compounds and analyzed at day 16. As expected, the expression of Gli1 mRNA (Figure [4](#F4){ref-type="fig"}A), a marker of the activation of Hedgehog signaling (Hooper and Scott, [@B16]), was observed. However, neither purmorphamine nor SAG were able to substitute to rosiglitazone and to modulate the expression of UCP1 or FABP4.

![**Effect of Hedgehog and BMP signaling in the conversion of white to brown adipocytes**. hMADS-2 cells were induced to differentiate into adipocytes in presence of 100 nM rosiglitazone at the indicate times. **(A)**, Purmorphamine (purmo) or smoothened agonist (SAG) as effectors of the Hedgehog signaling pathway were added between days 14 and 18. Their effects were analyzed by measuring UCP1, FABP4, and Gli1 mRNA expression. **(B)** hMADS-2 cells were treated or not with 10 nM BMP2 or BMP7 between days 0 and 16, and analyzed at day 16. Results are the mean ± SEM of three independent experiments and are expressed by taking as 100% the value obtained for 100 nM rosiglitazone treatment between days 14 and 18. \**p *\< 0.05 vs. cells treated only by rosiglitazone 100 nM.](fendo-02-00087-g004){#F4}

In a similar way we tested whether BMPs could induce the "browning" of hMADS cells. hMADS cells, in the presence or absence of rosiglitazone between days 3 and 9, were treated with or without 10 nM BMP2 or BMP7. As shown in Figure [4](#F4){ref-type="fig"}B, neither BMP2 nor BMP7 affected adipogenesis of hMADS cells, as illustrated by the expression of FABP4 and only induced weakly the formation of brite adipocytes as illustrated by the expression of UCP1 and CIDEA.

Discussion
==========

Recent advances in the developmental analysis of white and brown progenitors demonstrated a distinct origin (Timmons et al., [@B32]; Crisan et al., [@B7]). Furthermore, brown-like adipocytes are found in white fat depots upon physiological or pharmacological stimulation and there is evidence that white adipocytes can be converted to brown-like fat cells (Tiraby et al., [@B33]; Cinti, [@B4],[@B5]). A recent study described mouse "brite" adipocytes, obtained upon chronic PPARγ activation of primary cultures of white adipocyte precursors (Petrovic et al., [@B21]), which may explain the UCP1 expression found in islets surrounded by white adipocytes (Cousin et al., [@B6]; Xue et al., [@B40]). In adult humans, the increase of white to "brite" adipocyte conversion and activity, taking advantage of the important mass of WAT, could represent a novel strategy to combat overweight/obesity as a result of energy imbalance. Unfortunately, detailed investigations are hampered *ex vivo* by the unavailability of human brite and genuine brown adipocytes.

The observations reported herein emphasize that hMADS cells can differentiate into brite adipocytes. Their differentiation is associated with an increase of mitochondrial markers (Figure [3](#F3){ref-type="fig"}). During proliferation and differentiation, hMADS cells do not express Myf5 indicating that a common signature with myoblasts can be ruled out. Analyzing the expression pattern of genes known to be associated with brown or brite murine adipocytes, clearly demonstrate the brite signature of converted hMADS cells. Indeed, these cells express brown adipocytes markers (PPARα, CPT1B, ELOVL3, CIDEA, PGC1a, and UCP1) and do not (ZIC1, LHX8) or barely express other specific markers (PRDM16, MEOX2) of genuine mouse brown adipocytes. Moreover, hMADS cells express well-known components of brown adipocyte signaling, demonstrating that these cells are able to respond to various signals such as α- and β-adrenergic agonists, bile acids, fatty acids and prostaglandins, thyroid hormone, and the natriuretic peptide (Table [2](#T2){ref-type="table"}; Rodriguez et al., [@B26]; Elabd et al., [@B9]). Therefore, hMADS cells can be used as a human cell model to analyze various brown modulating signals that have been described in rodents. Our results clearly emphasize Hedgehog and BMPs signaling as striking examples of the discrepancies existing between human and rodents (Fontaine et al., [@B12]; Svensson et al., [@B31]). Actually, it has been previously shown that activation of Hedgehog signaling *in vivo* and *in vitro* impairs white but not brown adipocyte differentiation (Pospisilik et al., [@B23]). Herein we showed that treatment of hMADS cells with Hedgehog activators did not affect white or brite adipocyte formation (Figure [4](#F4){ref-type="fig"}A). Furthermore, our data show that BMP7 induces weakly brite adipocyte formation of hMADS cells, in contrast to earlier observations in mouse cell models (Tseng et al., [@B34]; Schulz et al., [@B29]) despite the fact that hMADS cells do express functional BMP receptors (Zaragosi et al., [@B42]; and data not shown).

Taken together, our data demonstrated that differentiated brown-like hMADS adipocytes are representative of the so-called brite adipocytes recently described in mice (Petrovic et al., [@B21]) though significant differences are observed with regard to signaling cues favoring brown adipogenesis. In conclusion, our human cell model could contribute to shed some light on the mechanisms involved in the browning process of white adipocytes and could help in identifying drugs involved in this phenomenon.
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